Phase I/II study of cediranib and olaparib in combination for treatment of recurrent platinum-sensitive papillary-serous ovarian, fallopian tube, or peritoneal cancer or for treatment of recurrent triple-negative breast cancer
Latest Information Update: 26 Apr 2025
At a glance
Most Recent Events
- 04 Mar 2025 Planned End Date changed from 13 Feb 2025 to 13 Feb 2026.
- 04 Mar 2025 Planned End Date changed from 13 Feb 2025 to 13 Feb 2026.
- 08 Mar 2024 Planned End Date changed from 17 Jan 2025 to 13 Feb 2025.